

**Development of ‘Redox Arrays’ for identifying novel glutathionylated proteins in the secretome**

**<sup>1</sup>Lisa Mullen\*, <sup>1</sup>Miles Seavill, <sup>1</sup>Raneem Hammouz, <sup>4</sup>Barbara Bottazzi, <sup>2,3</sup>Phillippe Chan, <sup>2,3</sup>David Vaudry, <sup>1</sup>Pietro Ghezzi**

<sup>1</sup>Brighton and Sussex Medical School, Falmer, Brighton BN1 9RY

<sup>2</sup>Institute for Research and Innovation in Biomedicine, Rouen University, 76821 Rouen, France

<sup>3</sup>Platform in Proteomics PISSARO, 76821 Mont-Saint-Aignan, France

<sup>4</sup> Humanitas Clinical & Research Center Via Manzoni, 113, 20089 Rozzano, Milano, Italy


\*Corresponding author. Email: l.mullen@bsms.ac.uk

### Supplementary methods.

Recombinant TNF (Peprotech, London, UK) or Prdx2 purified from transiently transfected 293T cells were tested for in vitro glutathionylation as described in the main Methods section.

### Supplementary Figure Legends

**Supplementary Figure 1. TNF is not glutathionylated in vitro.** Recombinant TNF or Prdx2 (as a positive control) were incubated with BioGEE and diamide, before analyses by Western blotting. Membranes were probed with streptavidin-HRP to detect the presence of the BioGEE label or anti-TNF antibody to confirm the presence of the protein.



Supplementary Figure 1